Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
EU Funding & Tenders Portal HORIZON-MISS-2027-02-CANCER-02 · Horizon Europe (HORIZON)
| Funder | European Commission |
|---|---|
| Status | forthcoming |
| Opens | 10 Feb 2027 |
| Deadline | 16 Sep 2027 — 321 days |
| Action | HORIZON Innovation Actions |
| Official page | https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunit… |
| Last checked | 2026-10-30 06:02:40+00:00 |
The scope text was read and no clause in it rules a field out. That is not a guarantee — read the call before you commit to it.
You are reading one call. 1,058 are open right now.
A search matches words. It cannot know what your institution works on. Give the name and every open call is ranked against it — this one included.
This call page is free · no account · the report arrives by emailWhat this call is
| Instrument | HORIZON-IA |
|---|---|
| Stages | single-stage |
| EU contribution | €7.0m to €10.0m per project |
| Projects expected | 3, sharing €20.0m |
From the Commission's own budget table for this call. Confirm against the topic page before you plan around it: these move when a work programme is amended.
Scope
Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: Patients afflicted by lung, bowel, breast or prostate cancer [1] , will benefit from the outcomes of evidence-based, tailored, innovative, affordable and accessible diagnosis- and treatment-centred clinical research programmes by comprehensive cancer infrastructures [2] . Researchers, physicians, patient representatives, civil society, charities, foundations, insurance companies, SMEs and innovators [3] will seize opportunities to respectively co-create, support, upscale or commercialise outcomes of evidence-based, tailored, affordable and accessible clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer. National and regional healthcare providers, healthcare payers, policymakers and authorities in European regions, EU Member States and Associated Countries have the evidence to engage in piloting, upscaling or implementing appropriate clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer. Scope: Lung, bowel, breast and prostate cancer incidence, mortality and prevalence across EU Member States and Associated Countries are increasing while showing substantial variation, with Central and Eastern European communities, regions and countries particularly affected [4] . At the same time, the level of development of comprehensive cancer infrastructures continues to vary considerably across EU Member States and Associated Countries, contributing to inequalities, in particular in terms of clinical research capacity as well as quality of and access to innovative diagnostic and therapeutic interventions. Applicants should address all of the following: Comprehensive cancer infrastructures across the EU Member States and Associated Countries come together to conduct clinical research on lung, bowel, breast or prostate cancer focusing on at least one of the following areas: Innovative diagnostics; Radiotherapy, surgery, chemotherapy; Therapeutic cancer vaccines for the treatment of cancer patients with early-stage, advanced, metastatic or minimal residual disease (e.g. after debulking by surgery, chemotherapy, radiotherapy, or immunotherapy); Implementation of appropriate clinical practice guidelines for diagnosis and treatment in countries without or with limited Comprehensive Cancer Infrastructures; Comprehensive cancer infrastructures should extensively pil…
What consortia for this call have looked like
4 projects
have been funded under this line
(HORIZON-MISS-CANCER-02) in Horizon Europe and H2020. This is what they
were made of — not a recommendation, just what the Commission signed.
range 7–21
19 seen across all of them
across those projects
The mix of organisations
Who coordinated them
Coordinating an EU project is a demanding, specific job. These organisations have done it on this topic line before.
This is the shape, not the consortium. It says how many partners these projects had and what kinds of organisation were in them. It does not know whether your idea needs the same mix, who is available, who is already committed elsewhere, or how the work and the budget should be divided. Those are judgement calls on a specific proposal, and no amount of public data answers them.
Building the actual consortium — finding the partners, agreeing the roles, and writing it so it survives an evaluation — is what Scientific Network Management does. Free either way; the radar does not change if you never ask.
Get told when something changes
Most institutions find out about a call with three weeks left. We write when something opens, moves or closes that fits what you work on, with the deadline, the fit and the funder's own exclusion clauses quoted. Nothing in a quiet week. Free, and one click to leave.
Starting from the programme you are reading: Horizon Europe (HORIZON) — change it below if you like.
Leave the second box empty and you get whatever opened or changed recently, closing soonest. Fill it in and it ranks against your words instead: that is the difference between a list and a shortlist.
Scientific Network Management will send you the current list for these terms, and after that only what changes: a call that opens, a deadline that shifts, a clause that rules you out. Nothing is sent when nothing has moved. One click to stop, in every message.
One confirmation email and nothing else until you click it. No tracking pixels, no sharing, one click to unsubscribe.
Of every 100 Horizon Europe proposals
A funding strategy reads your institution's own published record against the calls that are open, and says in writing which are worth the year and which to decline, with the reason for each.
Scientific Network Management, the grant-writing practice behind this radar: 13 years of EU-funded research projects, and a founder who has served as Key Expert and Team Leader on two EU-funded technical assistance contracts establishing biotechnology centres in Türkiye.
SNM also does
No obligation, and nothing here is conditional on using us: searching the calls stays free and asks for nothing either way.